Consenso sobre anticuerpos monoclonales en migraña del Grupo de Estudio de Cefaleas de la Asociación Madrileña de Neurología

González, Germán Latorre; García, Nuria González; Miguel, Carlos Calle de; Rodríguez, Beatriz Barcenilla; Fonfría, Alba Cárcamo; Limón, Javier Casas; Terán, Javier Díaz de; Sánchez, Álex Jaimes; Bandera, Carlos Ordás; Vico, Jaime Rodríguez; Flores, Laura Rubio; Real, María Sastre; Díaz, Elena Toribio; Peinado, Cristina Treviño; Gutiérrez, Sonia Quintas; Grande, Juan Antonio Pareja; Porta‐Etessam, Jesús; González, Margarita Sánchez del Río; Santos-Lasaosa, S; Gago-Veiga, Ana Beatriz

doi:10.24875/kranion.m23000050

KRANION

2024

DOI: 10.24875/kranion.m23000050

|View full text |Cite

Consenso sobre anticuerpos monoclonales en migraña del Grupo de Estudio de Cefaleas de la Asociación Madrileña de Neurología

Germán Latorre González¹,

Nuria González García²,

Carlos Calle de Miguel³

et al.

Abstract: Introducción: A finales de 2018 fue autorizado en España el uso de los primeros anticuerpos monoclonales contra el péptido relacionado con el gen de la calcitonina (CGRP) o su receptor como tratamiento preventivo de la migraña. Su posología y mecanismo de acción los diferencian de los fármacos orales actuales. El acceso a estos tratamientos requiere el cumplimiento de unas condiciones especiales para su financiación en nuestro medio. En este documento se revisan los aspectos fundamentales de estos fármacos. Ad… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine

Romero del Rincón,

Gonzalez‐Martinez,

Quintas

et al. 2024

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeAccording to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAb) may be considered after 12–18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption.MethodsThis was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti‐CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti‐CGRP MAb (T‐baseline); last month of first treatment period (T‐suspension); month of restart due to worsening (T‐worsening); and 3 months after resumption (T‐reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD.ResultsA total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T‐baseline was 20 (13) and MMD was 5 (6); at T‐suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T‐worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T‐reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001).ConclusionThe results suggest that anti‐CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.

show abstract

RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine

Romero del Rincón,

Gonzalez‐Martinez,

Quintas

et al. 2024

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Consenso sobre anticuerpos monoclonales en migraña del Grupo de Estudio de Cefaleas de la Asociación Madrileña de Neurología

Cited by 1 publication

References 65 publications

RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine

RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine

Contact Info

Product

Resources

About